FDA WARNING_LETTER - Dr. Paul's Lab - February 09, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On February 16, 2021, the FDA and FTC issued a Warning Letter to Dr. Sarah's Essentials regarding the sale of "COVID-Aid Tincture." The agencies reviewed the company's websites, http://drpaulslab.net and https://drsarahsessentials.com, on January 28 and February 9, 2021.
The FDA determined that "COVID-Aid Tincture" is an unapproved new drug, sold in violation of section 505(a) of the FD&C Act, 21 U.S.C. § 355(a), and a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The product is marketed with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, which is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).
The letter requires immediate action to cease the sale of all unapproved and unauthorized COVID-19 related products. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov detailing corrective steps, including documentation and recurrence prevention. Failure to
ID · ec911cb0-88cf-4846-bd98-a9666482b401
Full citation text and observation details available on the Dashboard.